<DOC>
	<DOCNO>NCT00827203</DOCNO>
	<brief_summary>The aim study determine safety tolerability elesclomol sodium escalating dos ( ultimately identify maximum tolerate dose ) . This study also characterize pharmacokinetics elesclomol evaluate anti-tumor activity advance solid tumor metastatic unresectable .</brief_summary>
	<brief_title>A Safety Study Determine Maximum Tolerated Dose Elesclomol Sodium Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Males females least 18 year age Histologically cytologically confirm solid tumor ( except melanoma ) metastatic unresectable Advanced metastatic cancer standard therapy exist progress despite standard therapy Acceptable organ marrow function Screening Period define protocol . Reliable venous access suitable weekly study drug infusion Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Exclusion Criteria Pregnant breastfeed woman Have chemotherapy radiotherapy within 4 week prior enter study Primary brain tumor active brain metastasis Treatment chronic immunosuppressant Significant cardiovascular disease , severe acute/chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>Elesclomol Sodium</keyword>
	<keyword>tumor</keyword>
	<keyword>Advanced solid tumor metastatic unresectable</keyword>
</DOC>